WhiteSands Treatment Center Publishes Guide on Pristiq Withdrawal

The new resource covers symptoms, treatment considerations for antidepressant discontinuation.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

WhiteSands Treatment Center has released an educational article addressing the clinical realities of Pristiq (desvenlafaxine) withdrawal and evidence-based treatment approaches. The resource provides a medically grounded review of potential withdrawal effects and the role of structured addiction treatment and mental health services in promoting patient safety during antidepressant discontinuation.

Why it matters

Pristiq is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder, a condition that affects millions of adults annually and can contribute to functional impairment and co-occurring substance use. Abrupt discontinuation of SNRIs may result in antidepressant discontinuation syndrome, underscoring the need for medically supervised tapering to reduce symptom severity.

The details

The article explains that while withdrawal from antidepressants is generally not fatal when managed appropriately, medically supervised tapering is recommended to minimize risks. It also contextualizes Pristiq withdrawal within the broader public health framework of overlapping mental health and substance use disorders, emphasizing the importance of integrated addiction treatment and psychiatric care.

  • The article was published on March 5, 2026.

The players

WhiteSands Treatment Center

A network of Florida-based addiction treatment and mental health service providers that offers a full continuum of care, including outpatient, detox, and residential services.

Got photos? Submit your photos here. ›

What’s next

The article highlights the importance of coordination between prescribing clinicians and addiction treatment providers to ensure safe medication management during early recovery.

The takeaway

This resource underscores the clinical complexities of antidepressant discontinuation and the need for integrated, evidence-based treatment approaches that address both mental health and substance use disorders to promote patient safety and long-term recovery.